Steroid-free three-drug maintenance regimen for pancreas transplant alone

Comparison of induction with rabbit antithymocyte globulin +/− rituximab

Jonathan A. Fridell, Richard Mangus, Jeanne M. Chen, Tim Taber, Arianna E. Cabrales, Asif Sharfuddin, Muhammad Yaqub, John A. Powelson

Research output: Contribution to journalArticle

Abstract

Graft survival following pancreas transplant alone (PTA) is inferior to other pancreas transplants. Steroid elimination is appealing, but a two-drug maintenance strategy may be inadequate. Additionally, recipients tend to have diabetic nephropathy and do not tolerate nephrotoxic medications. A three-drug maintenance strategy permits immunosuppression through different mechanisms as well as an opportunity to use lower doses of the individual medications. Induction consisted of five doses of rabbit antithymocyte globulin (1 mg/kg/dose). As of October 2007, a single dose of rituximab (150 mg/m2) was added. Maintenance consisted of tacrolimus, sirolimus and mycophenolate mofetil. From 2004 to 2017, 166 PTA were performed. Graft loss at 7 and 90 days were 4% and 5%, and 1-year patient and graft survival were 97% and 91%. Comparing induction without and with rituximab, there was no significant difference in 7- or 90-day graft loss, 1-year patient or graft survival, or in the rate of rejection or infection. Rabbit antithymocyte globulin induction and steroid withdrawal followed by a three-drug immunosuppression regimen is an excellent strategy for PTA recipients.

Original languageEnglish (US)
Pages (from-to)3000-3006
Number of pages7
JournalAmerican Journal of Transplantation
Volume18
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Antilymphocyte Serum
Pancreas
Steroids
Maintenance
Rabbits
Transplants
Graft Survival
Pharmaceutical Preparations
Immunosuppression
Mycophenolic Acid
Diabetic Nephropathies
Tacrolimus
Sirolimus
Rituximab
Infection

Keywords

  • clinical research/practice
  • immunosuppressive regimens-induction
  • immunosuppressive regimens-maintenance
  • pancreas/simultaneous pancreas-kidney transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Steroid-free three-drug maintenance regimen for pancreas transplant alone : Comparison of induction with rabbit antithymocyte globulin +/− rituximab. / Fridell, Jonathan A.; Mangus, Richard; Chen, Jeanne M.; Taber, Tim; Cabrales, Arianna E.; Sharfuddin, Asif; Yaqub, Muhammad; Powelson, John A.

In: American Journal of Transplantation, Vol. 18, No. 12, 01.12.2018, p. 3000-3006.

Research output: Contribution to journalArticle

@article{232509407995472eadeeb6869751168a,
title = "Steroid-free three-drug maintenance regimen for pancreas transplant alone: Comparison of induction with rabbit antithymocyte globulin +/− rituximab",
abstract = "Graft survival following pancreas transplant alone (PTA) is inferior to other pancreas transplants. Steroid elimination is appealing, but a two-drug maintenance strategy may be inadequate. Additionally, recipients tend to have diabetic nephropathy and do not tolerate nephrotoxic medications. A three-drug maintenance strategy permits immunosuppression through different mechanisms as well as an opportunity to use lower doses of the individual medications. Induction consisted of five doses of rabbit antithymocyte globulin (1 mg/kg/dose). As of October 2007, a single dose of rituximab (150 mg/m2) was added. Maintenance consisted of tacrolimus, sirolimus and mycophenolate mofetil. From 2004 to 2017, 166 PTA were performed. Graft loss at 7 and 90 days were 4{\%} and 5{\%}, and 1-year patient and graft survival were 97{\%} and 91{\%}. Comparing induction without and with rituximab, there was no significant difference in 7- or 90-day graft loss, 1-year patient or graft survival, or in the rate of rejection or infection. Rabbit antithymocyte globulin induction and steroid withdrawal followed by a three-drug immunosuppression regimen is an excellent strategy for PTA recipients.",
keywords = "clinical research/practice, immunosuppressive regimens-induction, immunosuppressive regimens-maintenance, pancreas/simultaneous pancreas-kidney transplantation",
author = "Fridell, {Jonathan A.} and Richard Mangus and Chen, {Jeanne M.} and Tim Taber and Cabrales, {Arianna E.} and Asif Sharfuddin and Muhammad Yaqub and Powelson, {John A.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1111/ajt.14921",
language = "English (US)",
volume = "18",
pages = "3000--3006",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Steroid-free three-drug maintenance regimen for pancreas transplant alone

T2 - Comparison of induction with rabbit antithymocyte globulin +/− rituximab

AU - Fridell, Jonathan A.

AU - Mangus, Richard

AU - Chen, Jeanne M.

AU - Taber, Tim

AU - Cabrales, Arianna E.

AU - Sharfuddin, Asif

AU - Yaqub, Muhammad

AU - Powelson, John A.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Graft survival following pancreas transplant alone (PTA) is inferior to other pancreas transplants. Steroid elimination is appealing, but a two-drug maintenance strategy may be inadequate. Additionally, recipients tend to have diabetic nephropathy and do not tolerate nephrotoxic medications. A three-drug maintenance strategy permits immunosuppression through different mechanisms as well as an opportunity to use lower doses of the individual medications. Induction consisted of five doses of rabbit antithymocyte globulin (1 mg/kg/dose). As of October 2007, a single dose of rituximab (150 mg/m2) was added. Maintenance consisted of tacrolimus, sirolimus and mycophenolate mofetil. From 2004 to 2017, 166 PTA were performed. Graft loss at 7 and 90 days were 4% and 5%, and 1-year patient and graft survival were 97% and 91%. Comparing induction without and with rituximab, there was no significant difference in 7- or 90-day graft loss, 1-year patient or graft survival, or in the rate of rejection or infection. Rabbit antithymocyte globulin induction and steroid withdrawal followed by a three-drug immunosuppression regimen is an excellent strategy for PTA recipients.

AB - Graft survival following pancreas transplant alone (PTA) is inferior to other pancreas transplants. Steroid elimination is appealing, but a two-drug maintenance strategy may be inadequate. Additionally, recipients tend to have diabetic nephropathy and do not tolerate nephrotoxic medications. A three-drug maintenance strategy permits immunosuppression through different mechanisms as well as an opportunity to use lower doses of the individual medications. Induction consisted of five doses of rabbit antithymocyte globulin (1 mg/kg/dose). As of October 2007, a single dose of rituximab (150 mg/m2) was added. Maintenance consisted of tacrolimus, sirolimus and mycophenolate mofetil. From 2004 to 2017, 166 PTA were performed. Graft loss at 7 and 90 days were 4% and 5%, and 1-year patient and graft survival were 97% and 91%. Comparing induction without and with rituximab, there was no significant difference in 7- or 90-day graft loss, 1-year patient or graft survival, or in the rate of rejection or infection. Rabbit antithymocyte globulin induction and steroid withdrawal followed by a three-drug immunosuppression regimen is an excellent strategy for PTA recipients.

KW - clinical research/practice

KW - immunosuppressive regimens-induction

KW - immunosuppressive regimens-maintenance

KW - pancreas/simultaneous pancreas-kidney transplantation

UR - http://www.scopus.com/inward/record.url?scp=85057193353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057193353&partnerID=8YFLogxK

U2 - 10.1111/ajt.14921

DO - 10.1111/ajt.14921

M3 - Article

VL - 18

SP - 3000

EP - 3006

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 12

ER -